Systematic analysis of funding awarded for antimicrobial research in the UK

Dr Michael Head, Farr Institute, University College London & IDRN

AMR initiatives – Developing new ways of working

Dr Ghada Zoubiane, Programme Manager for Infections and Immunology Board, Medical Research Council

The changing face of pharma industry research

Dr Ursula Theuretzbacher, Center for Anti-Infective Agents, Vienna

The importance of accurate and rapid diagnostics: the role of genomics and other new tools

Professor Peter Hawkey, Professor of Clinical and Public Health Bacteriology/Consultant Medical Microbiologist, Public Health England, Birmingham

Panel Discussion

New business models for antibiotics: results from the Chatham House working group

Professor Kevin Outterson, Professor of Law & N. Neal Pike Scholar in Health and Disability Law, Boston University & Visiting Fellow,Chatham House

It’s definitely broken – so fi x it! The role of regulation in driving new economic models for antimicrobial discovery

Dr Richard Bax, Transcrip Partners Ltd

Innovative approaches from industry: developing new diagnostics

Professor Alex van Belkum, Corporate Vice President R&D Microbiology, bioMérieux

Real world incentives for antibiotic development

Dr Nicole Mahoney, Director, Government Aff airs & Regulatory Policy, Cubist Pharmaceuticals

Closing Discussion